ICON Public Limited Company
ICLRNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $204.63 Prior regular-session close from the quote source.
- $199.42–$208.38 Regular-session low and high so far today.
- 647.2K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $66.57–$219.04 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own ICLR if global clinical-trial outsourcing remains concentrated among scaled CROs and FY2025’s profit reset proves temporary rather than structural.
ICLR price history
Loading recent earnings…
Investment thesis
What must happen next
Pharma and biotech sponsors continue to outsource complex clinical-development work to scaled CROs, allowing ICON’s global platform to convert drug R&D activity into contracted revenue rather than losing work to insourcing or smaller specialists.HoldingMateriality: High
GAAP annual revenue increased from $5.481 billion in FY2021 to $8.251 billion in FY2025. If outsourcing demand and ICON’s share position hold, the company has a durable revenue base; if sponsors insource or shift work to rivals, scale stops protecting the model.
Watch: Large pharma sponsors bring more clinical operations in-house after consolidating vendor panels.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $5.481 billion in FY2021 to $8.251 billion in FY2025.
Open source ↗ICON’s scale only creates durable value if the company keeps specialist staff and trial infrastructure well utilized while pricing study complexity adequately; FY2025 raises the risk that execution costs or sponsor pricing pressure are eroding that mechanism.WeakeningMateriality: High
GAAP annual operating income rose from $795.2 million in FY2022 to $1.032 billion in FY2024, showing the model previously converted scale into profit. Revenue without utilization and pricing discipline does not compound owner value; margin recovery is central to whether the business model still has economic power.
Watch: Sponsors rebid large trial programs at lower rates or demand more risk-sharing from CRO vendors.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income rose from $795.2 million in FY2022 to $1.032 billion in FY2024, showing the model previously converted.
Open source ↗ICON’s contract structure and working-capital discipline should keep converting the revenue base into substantial operating cash flow, giving the company resilience even when GAAP earnings are pressured.StrengtheningMateriality: Medium
GAAP annual operating cash flow was $1.161 billion in FY2023, $1.287 billion in FY2024, and $1.036 billion in FY2025. Sustained cash generation funds debt reduction, reinvestment, and potential buybacks; if cash conversion breaks, accounting earnings risk becomes a balance-sheet risk.
Watch: Sponsors delay payments, renegotiate milestones, or cancel programs in response to funding pressure.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was $1.161 billion in FY2023, $1.287 billion in FY2024, and $1.036 billion in FY2025.
Open source ↗Continued deleveraging preserves ICON’s strategic flexibility and reduces financial risk, provided management does not re-lever for acquisitions or buybacks before the operating-margin issue is resolved.StrengtheningMateriality: Medium
GAAP total liabilities declined from $8.687 billion at FY2022 year-end to $7.076 billion at FY2025 year-end. A stronger balance sheet gives owners more ways to win from recovery; renewed leverage would amplify downside if trial demand or margins deteriorate.
Watch: Management pursues a large debt-funded acquisition before organic growth and margins have stabilized.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP total liabilities declined from $8.687 billion at FY2022 year-end to $7.076 billion at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Pharma and biotech sponsors continue to outsource complex clinical-development work to scaled CROs, allowing ICON’s global platform to convert drug R&D activity into contracted revenue rather than losing work to insourcing or smaller specialists. If outsourcing demand and ICON’s share position hold, the company has a durable revenue base; if sponsors insource or shift work to rivals, scale stops protecting the model.
ICON’s scale only creates durable value if the company keeps specialist staff and trial infrastructure well utilized while pricing study complexity adequately; FY2025 raises the risk that execution costs or sponsor pricing pressure are eroding that mechanism. Revenue without utilization and pricing discipline does not compound owner value; margin recovery is central to whether the business model still has economic power.
ICON’s contract structure and working-capital discipline should keep converting the revenue base into substantial operating cash flow, giving the company resilience even when GAAP earnings are pressured. Sustained cash generation funds debt reduction, reinvestment, and potential buybacks; if cash conversion breaks, accounting earnings risk becomes a balance-sheet risk.
Continued deleveraging preserves ICON’s strategic flexibility and reduces financial risk, provided management does not re-lever for acquisitions or buybacks before the operating-margin issue is resolved. A stronger balance sheet gives owners more ways to win from recovery; renewed leverage would amplify downside if trial demand or margins deteriorate.
All standing thesis claims
Original report summary
global clinical-trial outsourcing remains concentrated among scaled CROs and FY2025’s profit reset proves temporary rather than structural.
Bull case and bear case
Bull case and bear case for Icon
Where the evidence on Icon disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 2 strengthening, 1 holding and 1 weakening.
Bull case: what the evidence supports
Pharma and biotech sponsors continue to outsource complex clinical-development work to scaled CROs, allowing ICON’s global platform to convert drug R&D activity into contracted revenue rather than losing work to insourcing or smaller specialists.
ICON’s contract structure and working-capital discipline should keep converting the revenue base into substantial operating cash flow, giving the company resilience even when GAAP earnings are pressured.
Continued deleveraging preserves ICON’s strategic flexibility and reduces financial risk, provided management does not re-lever for acquisitions or buybacks before the operating-margin issue is resolved.
Bear case: what the evidence questions
ICON’s scale only creates durable value if the company keeps specialist staff and trial infrastructure well utilized while pricing study complexity adequately; FY2025 raises the risk that execution costs or sponsor pricing pressure are eroding that mechanism.
Thesis-Break Engine
What has broken in Icon’s thesis
Each break OptimistFi flagged on Icon, dated — with what has historically followed the same kind of break across the market, not a forecast for Icon.
- Price target fell below the stockcondition set before this filing
Across all companies, this kind of break has happened 1,809 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
- Insider-selling clustercondition set before this filing
Across all companies, this kind of break has happened 9,137 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 30% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Icon’s latest quarterly report, ahead of the annual figure it is written on.
- Operating-margin compression, trailing 12 months
Across all companies, this kind of early warning has happened 2,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 36% of them trailed it by 10 points or more.
Several kinds of break have stacked on Icon at once. A cluster is a stronger read than any one signal alone.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedForeign issuer material report (6-K).
Icon filed an SEC report on 2026-10-08: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Icon filed an SEC report on 2026-09-09: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Icon filed an SEC report on 2026-08-20: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large pharma sponsors bring more clinical operations in-house after consolidating vendor panels.
- Sponsors rebid large trial programs at lower rates or demand more risk-sharing from CRO vendors.
- Sponsors delay payments, renegotiate milestones, or cancel programs in response to funding pressure.
- Management pursues a large debt-funded acquisition before organic growth and margins have stabilized.
ICLR news
Loading headlines…
Financial statements
ICLR income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ICLR: quick answers
- Have members of Congress traded ICLR?
- Reports made public in the last 90 days disclose 1 trade in ICLR by 1 filer: 0 purchases and 1 sale. They are filed under the STOCK Act by members of Congress, the President and senior officials. Every disclosed ICLR trade